Lupin to Invest $250 Million in New U.S. Manufacturing Facility at Coral Springs, Florida

Lupin Limited announced plans to establish a state-of-the-art pharmaceutical facility in Coral Springs, Florida, reinforcing its long-term strategy to expand its U.S. footprint and advance innovation in respiratory medicine. Key Highlights Investment: $250 million over five years, covering R&D, infrastructure, and capital spend. Production Capacity: Over 25 critical respiratory medicines, including lifesaving albuterol inhalers for children and U.S. service members. Economic Impact: Creation of 200+ skilled jobs in Broward County by 2030, strengthening Florida’s local economy and medical resilience. Strategic Focus: Supports Lupin’s global aim to diversify supply chains, boost domestic U.S. manufacturing, and ensure reliable access to essential therapies. Corporate Significance The new facility will enhance Lupin’s Florida headquarters and Advanced Inhalation Research Center, both based in Coral Springs. The project has secured state incentives and tax credits, highlighting robust public-private collaboration. With 15 global manufacturing sites and 7 research centers, Lupin continues to advance innovation and supply-chain reliability across over 100 markets worldwide. ✅ Disclaimer: This update is for informational purposes only and not investment advice. 👉 Follow for more global corporate and healthcare insights.